Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus

Sulphonylureas (SUs) subclasses have different risks of all-cause mortality, acute myocardial infarction (AMI), and stroke. Therefore, we assessed these risks in patients with type 2 diabetes mellitus administered gliclazide, glimepiride, or metformin monotherapy with retrospective cohort study desi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Eun-Hee, Han, Kyungdo, Kim, Bongseong, Lee, Dae Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373575/
https://www.ncbi.nlm.nih.gov/pubmed/32702900
http://dx.doi.org/10.1097/MD.0000000000021236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373575/
https://www.ncbi.nlm.nih.gov/pubmed/32702900
http://dx.doi.org/10.1097/MD.0000000000021236

Ejemplares similares